These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25268235)

  • 1. Global financing and long-term technical assistance for multidrug-resistant tuberculosis: scaling up access to treatment.
    Hwang TJ; Keshavjee S
    PLoS Med; 2014 Sep; 11(9):e1001738. PubMed ID: 25268235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curing multidrug-resistant tuberculosis: not all about the money.
    Gruber K
    Lancet Respir Med; 2016 Nov; 4(11):870-871. PubMed ID: 27799128
    [No Abstract]   [Full Text] [Related]  

  • 3. Programmatic management of multidrug-resistant tuberculosis: models from three countries.
    Furin J; Bayona J; Becerra M; Farmer P; Golubkov A; Hurtado R; Joseph JK; Keshavjee S; Ponomarenko O; Rich M; Shin S
    Int J Tuberc Lung Dis; 2011 Oct; 15(10):1294-300. PubMed ID: 21669029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Universal' access for MDR-TB limited without the involvement of the private sector.
    Pinto L; Udwadia Z
    Int J Tuberc Lung Dis; 2011 Jun; 15(6):851; author reply 851-2. PubMed ID: 21575312
    [No Abstract]   [Full Text] [Related]  

  • 5. Multidrug resistant tuberculosis: a continuing crisis.
    Burki T
    Lancet Infect Dis; 2016 Dec; 16(12):1337-1338. PubMed ID: 27998601
    [No Abstract]   [Full Text] [Related]  

  • 6. Ending tuberculosis by 2030: can we do it?
    Suthar AB; Zachariah R; Harries AD
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1148-54. PubMed ID: 27510238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-resistant tuberculosis: desperate measures?
    Cullinan T
    Lancet; 2001 Apr; 357(9262):1124. PubMed ID: 11297986
    [No Abstract]   [Full Text] [Related]  

  • 8. The challenge of multidrug resistant tuberculosis.
    Davies PD
    Hosp Med; 2001 Jul; 62(7):390-1. PubMed ID: 11480123
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to drug resistant tuberculosis is insufficient and too slow.
    Cui W
    BMJ; 2011 Mar; 342():d1969. PubMed ID: 21444638
    [No Abstract]   [Full Text] [Related]  

  • 10. Multidrug-resistant tuberculosis.
    Wkly Epidemiol Rec; 2001 Sep; 76(36):273. PubMed ID: 11573306
    [No Abstract]   [Full Text] [Related]  

  • 11. The dollars and sense of managing drug-resistant tuberculosis in Singapore.
    Ong CW; Tambyah PA
    Ann Acad Med Singap; 2011 Mar; 40(3):113-5. PubMed ID: 21603727
    [No Abstract]   [Full Text] [Related]  

  • 12. Public health. Responding to market failures in tuberculosis control.
    Gupta R; Kim JY; Espinal MA; Caudron JM; Pecoul B; Farmer PE; Raviglione MC
    Science; 2001 Aug; 293(5532):1049-51. PubMed ID: 11463877
    [No Abstract]   [Full Text] [Related]  

  • 13. Limited access to drugs for resistant tuberculosis: a call to action.
    Bélard S; Janssen S; Osbak KK; Adegnika AA; Ondounda M; Grobusch MP
    J Public Health (Oxf); 2015 Dec; 37(4):691-3. PubMed ID: 25527468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug-resistant tuberculosis--can the tide be turned?
    Zumla A; Grange JM
    Lancet Infect Dis; 2001 Oct; 1(3):199-202. PubMed ID: 11871496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives.
    Lessem E; Cox H; Daniels C; Furin J; McKenna L; Mitnick CD; Mosidi T; Reed C; Seaworth B; Stillo J; Tisile P; von Delft D
    Int J Infect Dis; 2015 Mar; 32():56-60. PubMed ID: 25809757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beyond directly observed therapy for tuberculosis.
    Nolan CM
    Chest; 1997 May; 111(5):1151-3. PubMed ID: 9149558
    [No Abstract]   [Full Text] [Related]  

  • 17. Scaling up programmatic management of drug-resistant tuberculosis: a prioritized research agenda.
    Cobelens FG; Heldal E; Kimerling ME; Mitnick CD; Podewils LJ; Ramachandran R; Rieder HL; Weyer K; Zignol M;
    PLoS Med; 2008 Jul; 5(7):e150. PubMed ID: 18613746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlling multidrug-resistant tuberculosis and access to expensive drugs: a rational framework.
    Pablos-Mendez A; Gowda DK; Frieden TR
    Bull World Health Organ; 2002; 80(6):489-95; discussion 495-500. PubMed ID: 12132008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Getting health services to three million people with TB.
    Pérez H
    J Int AIDS Soc; 2014; 17(1):19079. PubMed ID: 24666595
    [No Abstract]   [Full Text] [Related]  

  • 20. Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection?
    Lobato MN; Jereb JA; Castro KG
    Pediatrics; 2009 Mar; 123(3):902-3. PubMed ID: 19255018
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.